CRI's Vanessa Lucey, Ph.D., discusses the immuno-onocology landscape in this webinar for the biotechnology industry.
CRI’s Vanessa Lucey will be a panelist during the "Landscape and Evolution of the Marketplace" talk at IO360 on February 27, 2020.
Vanessa M. Lucey, Ph.D., MBA, director of CRI Clinical Accelerator and Venture Fund, will also speak on a panel on May 6, 2020, at Convene in New York City.
CRI's Vanessa Lucey is presenting a poster on our prostate cancer clinical trial in conjunction with our partners.
CRI's Jun Tang, Ph.D., senior manager, CRI Venture Fund and Clinical Accelerator, is presenting the latest update on the PD1/L1 landscape.
Hosted by the Cancer Research Institute this intimate, invitation-only event for media and health care investment analysts will explore what’s next in the IO field.
Drs. Jill O'Donnell-Tormey and Vanessa M. Lucey are participating in panel discussions at Cancer Progress.
Laura Peace, Consultant, Head of Clinical Alliances, Clinical Accelerator, participates in a panel discussion, 10:30 a.m.-11:15 a.m.
Update on a CRI-funded pancreatic cancer trial led by Robert H. Vonderheide, M.D., D.Phil, on March 31 at 2:27 p.m.
CEO Jill O’Donnell-Tormey, Ph.D., participates in the Women in Science panel on March 3, 2019 at 2:30 p.m.
CRI scientists present at the Annual Meeting of the American Society of Clinical Oncologists. CRI provides a daily recap of new work coming out of the conference.
CRI-funded and -affiliated scientists and clinicians showcased at the American Association of Cancer Research Annual Meeting on April 14-18, 2018, in Chicago.
On April 12, our chief medical officer, Aiman Shalabi, is a featured expert on the panel, “Immuno-Oncology: Challenges & Opportunities”.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Colorectal cancer veteran Gordon Levine discusses genomic testing, clinical trials, patient advocacy, and access to immunotherapy.
We spoke with Dr. Amanda Lund to learn more about her work and what she hopes to accomplish during the next five years as a CRI Lloyd J. Old STAR.